Analysis of nucleotide diversity of NAT2 coding region reveals homogeneity across Native American populations and high intra-population diversity

[1]  G. Suarez-Kurtz.  Pharmacogenomics in admixed populations. , 2007, Trends in pharmacological sciences.

[2]  G. Barbujani,et al.  Genomic Boundaries between Human Populations , 2006, Human Heredity.

[3]  Pardis C Sabeti,et al.  Deciphering the ancient and complex evolutionary history of human arylamine N-acetyltransferase genes. , 2006, American journal of human genetics.

[4]  Sohini Ramachandran,et al.  Support from the relationship of genetic and geographic distance in human populations for a serial founder effect originating in Africa. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[5]  W. Maddrey.  Drug-induced hepatotoxicity: 2005. , 2005, Journal of clinical gastroenterology.

[6]  P. V. van Helden,et al.  The influence of human N-acetyltransferase genotype on the early bactericidal activity of isoniazid. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  J. States,et al.  The T341C (Ile114Thr) polymorphism of N-acetyltransferase 2 yields slow acetylator phenotype by enhanced protein degradation. , 2004, Pharmacogenetics.

[8]  S. Pääbo,et al.  Evidence for gradients of human genetic diversity within and among continents. , 2004, Genome research.

[9]  J. Long,et al.  Population genetics, history, and health patterns in native americans. , 2004, Annual review of genomics and human genetics.

[10]  R. Andrade,et al.  Drug-induced hepatotoxicity , 2003, The New England journal of medicine.

[11]  Peter Donnelly,et al.  A comparison of bayesian methods for haplotype reconstruction from population genotype data. , 2003, American journal of human genetics.

[12]  M. Hammer,et al.  High-resolution SNPs and microsatellite haplotypes point to a single, recent entry of Native American Y chromosomes into the Americas. , 2003, Molecular biology and evolution.

[13]  I. Dupanloup,et al.  Mitochondrial DNA diversity in South America and the genetic history of Andean highlanders. , 2003, Molecular biology and evolution.

[14]  M. Olivier.  A haplotype map of the human genome. , 2003, Nature.

[15]  M. Olivier.  A haplotype map of the human genome , 2003, Nature.

[16]  Charles L Daley,et al.  American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. , 2003, American journal of respiratory and critical care medicine.

[17]  C. Antunes,et al.  Color and genomic ancestry in Brazilians , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[18]  M. Feldman,et al.  Genetic Structure of Human Populations , 2002, Science.

[19]  D. Hein.  Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis. , 2002, Mutation research.

[20]  C. Ki,et al.  Complete sequencing of a genetic polymorphism in NAT2 in the Korean population. , 2002, Clinical chemistry.

[21]  Jonathan Scott Friedlaender,et al.  A Human Genome Diversity Cell Line Panel , 2002, Science.

[22]  F. Chang,et al.  Polymorphism of the N‐acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug–induced hepatitis , 2002, Hepatology.

[23]  M. Siddiqui,et al.  Isoniazid-Induced Lupus Erythematosus Presenting With Cardiac Tamponade , 2002, American journal of therapeutics.

[24]  C. Gilks,et al.  Cotrimoxazole prophylaxis in adults infected with HIV in low-income countries , 2001, Current opinion in infectious diseases.

[25]  C. Tyler-Smith,et al.  Genetic differentiation in South Amerindians is related to environmental and cultural diversity: evidence from the Y chromosome. , 2001, American journal of human genetics.

[26]  Yusuke Nakamura,et al.  Identification of single-nucleotide polymorphisms (SNPs) of human N-acetyltransferase genes NAT1, NAT2, AANAT, ARD1, and L1CAM in the Japanese population , 2001, Journal of Human Genetics.

[27]  M. Doll,et al.  Functional characterization of human N-acetyltransferase 2 (NAT2) single nucleotide polymorphisms. , 2001, Pharmacogenetics.

[28]  K. Crandall,et al.  TCS: a computer program to estimate gene genealogies , 2000, Molecular ecology.

[29]  D. Luiselli,et al.  Genetic structure of Quechua-speakers of the Central Andes and geographic patterns of gene frequencies in South Amerindian populations. , 2000, American journal of physical anthropology.

[30]  K. Tokunaga,et al.  Novel allele containing a 190C>T nonsynonymous substitution in the N‐acetyltransferase (NAT2) gene , 2000, Human mutation.

[31]  P. Donnelly,et al.  Inference of population structure using multilocus genotype data. , 2000, Genetics.

[32]  R. MacArthur,et al.  Acetylator phenotype and genotype in patients infected with HIV: discordance between methods for phenotype determination and genotype. , 2000, Pharmacogenetics.

[33]  Y. Yamamoto,et al.  Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity. , 2000, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[34]  W S Watkins,et al.  The distribution of human genetic diversity: a comparison of mitochondrial, autosomal, and Y-chromosome data. , 2000, American journal of human genetics.

[35]  R. Cann,et al.  mtDNA history of the Cayapa Amerinds of Ecuador: detection of additional founding lineages for the Native American populations. , 1999, American journal of human genetics.

[36]  I. Roots,et al.  Pitfalls in N-acetyltransferase 2 genotyping. , 1999, Pharmacogenetics.

[37]  R. J. Mitchell,et al.  The central Siberian origin for native American Y chromosomes. , 1999, American journal of human genetics.

[38]  D. Grant,et al.  Human acetyltransferase polymorphisms. , 1997, Mutation research.

[39]  P. V. van Helden,et al.  Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosis. , 1997, American journal of respiratory and critical care medicine.

[40]  W. Haefeli,et al.  N‐Acetyltransferase 2 polymorphism in patients infected with human immunodeficiency virus , 1996, Clinical pharmacology and therapeutics.

[41]  D. Grant,et al.  Genotyping of the polymorphic N-acetyltransferase (NAT2*) gene locus in two native African populations. , 1996, Pharmacogenetics.

[42]  D. F. Roberts,et al.  The History and Geography of Human Genes , 1996 .

[43]  Sarman Singh,et al.  Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study. , 1996, Thorax.

[44]  W. M. Lee,et al.  Drug-induced hepatotoxicity. , 1995, The New England journal of medicine.

[45]  J. Brockmöller,et al.  Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. , 1995, American journal of human genetics.

[46]  B. Korf,et al.  Preliminary phenotypic map of chromosome 4p16 based on 4p deletions. , 1995, American journal of medical genetics.

[47]  G. Bertorelle,et al.  Analysis of DNA diversity by spatial autocorrelation. , 1995, Genetics.

[48]  R. Cann.  The history and geography of human genes , 1995, The Journal of Asian Studies.

[49]  B. Lin,et al.  Ethnic distribution of slow acetylator mutations in the polymorphic N-acetyltransferase (NAT2) gene. , 1994, Pharmacogenetics.

[50]  M. Eichelbaum,et al.  Polymorphic N-acetyltransferase (NAT2) in Amerindian populations of Panama and Colombia: high frequencies of point mutation 857A, as found in allele S3/M3. , 1993, Pharmacogenetics.

[51]  D. Grant,et al.  Human arylamine N-acetyltransferase genes: isolation, chromosomal localization, and functional expression. , 1990, DNA and cell biology.

[52]  F. Tajima.  Statistical method for testing the neutral mutation hypothesis by DNA polymorphism. , 1989, Genetics.

[53]  M. Nei.  Molecular Evolutionary Genetics , 1987 .

[54]  C. Hirayama,et al.  Elevated serum aminotransferase induced by isoniazid in relation to isoniazid acetylator phenotype , 1986, Hepatology.

[55]  F. Tajima.  Evolutionary relationship of DNA sequences in finite populations. , 1983, Genetics.

[56]  M. Rosenzweig,et al.  Contemporary Quantitative Ecology and Related Ecometrics. , 1981 .

[57]  R. Sokal,et al.  Spatial autocorrelation in biology: 1. Methodology , 1978 .

[58]  U. Thorgeirsson,et al.  Acetylation rates and monthly liver function tests during one year of isoniazid preventive therapy. , 1975, Chest.

[59]  G. A. Watterson.  On the number of segregating sites in genetical models without recombination. , 1975, Theoretical population biology.

[60]  R. Grantham.  Amino Acid Difference Formula to Help Explain Protein Evolution , 1974, Science.

[61]  V. McKusick,et al.  Genetic Control of Isoniazid Metabolism in Man , 1960, British medical journal.

[62]  S. Wright,et al.  Isolation by Distance. , 1943, Genetics.

[63]  M. Eichelbaum,et al.  Analysis of six SNPs of NAT2 in Ngawbe and Embera Amerindians of Panama and determination of the Embera acetylation phenotype using caffeine. , 2002, Pharmacogenetics.

[64]  W. Yew.  Risk factors for hepatotoxicity during anti-tuberculosis chemotherapy in Asian populations. , 2001, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[65]  Yew Ww.  Risk factors for hepatotoxicity during anti-tuberculosis chemotherapy in Asian populations. , 2001 .

[66]  R. MacArthur,et al.  Correction: Acetylator phenotype and genoype in patients infected with HIV: Discordance between methods for phenotype determination and genotype (Pharmacogenetics (2000) 10 (171-182)) , 2000 .

[67]  M. Doll,et al.  Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[68]  D. Mitchison.  How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis. , 1998, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[69]  U. Meyer,et al.  Molecular mechanisms of genetic polymorphisms of drug metabolism. , 1997, Annual review of pharmacology and toxicology.

[70]  L. Soto-Ramírez,et al.  [Treatment of tuberculosis]. , 1997, Gaceta medica de Mexico.

[71]  R. Sokal.  Ecological parameters inferred from spatial correlograms , 1979 .